
    
      OBJECTIVES:

      Primary

        -  Determine the safety of bevacizumab and irinotecan hydrochloride in patients with
           recurrent or refractory grade 3 or 4 malignant gliomas.

      Secondary

        -  Determine the activity of this regimen, in terms of progression-free survival, in these
           patients.

      OUTLINE: Patients receive bevacizumab and irinotecan hydrochloride every 2 weeks. Treatment
      continues in the absence of disease progression or unacceptable toxicity.

      PROJECTED ACCRUAL: A total of 68 patients will be accrued for this study.
    
  